Forbes reporter Nancy Wang spotlights Tara Bishop '97 and Eileen Tanghal '97, co-founders of Black Opal Ventures, a venture capital firm focused on health tech. “Tara and Eileen’s story at Black Opal Ventures is a testament to how diversity and innovation can disrupt traditional landscapes,” writes Wang. “Their pioneering strategies and investments herald a new era for healthcare venture capitalism, where diversity and technology converge to create a more inclusive and impactful future.”
Researchers from MIT and elsewhere have developed a swallowable “technopill” that can monitor vital signs from inside the body, reports Dennis Thompson for HealthDay. “The ability to facilitate diagnosis and monitor many conditions without having to go into a hospital can provide patients with easier access to healthcare and support treatment,” says Prof. Giovanni Traverso.
New Scientist reporter Alice Klein writes that MIT researchers have developed an ingestible electronic device that “can measure your breathing and heart rate from inside your gut [and] could potentially diagnose sleep apnea and even detect opioid overdoses.” The device could one day allow “people to be assessed for sleep apnea wirelessly and cheaply while at home.”
Researchers at MIT and elsewhere have developed a swallowable electronic capsule that can be used to help diagnose sleep apnea and other sleep disorders, reports Ian Randall for Newsweek. “Conventional laboratory and home sleep studies require the patient to be attached to many different sensors,” says Prof. Giovanni Traverso. “As you can imagine, trying to sleep with all of this machinery can be challenging. [The] ingestible capsule just requires that the patient swallow the vitamin-sized pill. It's easy and unobtrusive and can accurately measure both respiratory rate and heart rate while the patient sleeps."
Graduate student Milena Pagán '11 speaks with Boston Globe reporter Kara Baskin about bringing her Providence-based bagel shop, Reblle, to Kendall Square. “We started the process to move a store to Cambridge about two years ago” says Pagán. “This has really been a long time in the making, to find the right space and to work out a deal. But we’re in a really cool building. We have tenants upstairs. There’s a park across the street that reminds me in a lot of ways of the neighborhood where Rebelle is right now. And being close to MIT is such a dream. That place has really good juju for me, so I’m really excited about it.
Institute Prof. Robert Langer speaks with Freakonomics host Stephen Dubner about his approach to failure and perseverance in his professional career. Langer recalls how despite early failures with developing new drug delivery methods, “I really believed that if we could do this, it would make a big difference in science, and I hoped a big difference in medicine.”
Graduate student Milena Pagán '11 bringing her Providence-based bagel shop, Rebelle, to Kendall Square this winter, reports Kara Baskin for The Boston Globe. “Pagán was a 2023 Best Chef: Northeast James Beard semifinalist for her Puerto Rican café, Little Sister, also based in Providence,” writes Baskin.
Jasmina Aganovic ’09 founded Future Society, a brand that uses sequenced DNA from extinct flowers to create new scents, reports Celia Shatzman for Forbes. “[With] plants that are from another time, never before have we been able to time travel through smell,” says Aganovic. “But now we can do that, thanks specifically to DNA sequencing. It’s an example of where we're starting off with this concept of limitless nature. It isn't just about stories; it's also about performance.”
Xiangkun (Elvis) Cao, a Schmidt Science Fellow in MIT’s Department of Chemical Engineering, writes for Times Higher Education about the need to eliminate barriers between different academic disciplines. “More work needs to be done to support interdisciplinary researchers more generally,” writes Cao. “The lack of funding, incentives and community support holds back the scientific breakthroughs they could otherwise be making.”
7 News spotlights how MIT researchers have developed a new implantable device that could provide diabetes patients with insulin without using injections. “What we’ve been able to show is that with a minimally invasive implant that is sitting just under the skin, we’ve actually been able to sort of achieve a diabetic reversal,” explains Research Scientist Siddharth Krishnan.
Gizmodo reporter Ed Cara writes that MIT researchers have developed a new implantable device that can produce its own supply of insulin for up to a month. The team envisions that the device could “eventually be used for other medical conditions dependent on a regular supply of externally produced proteins, such as certain forms of anemia treated with erythropoietin,” writes Cara.
MIT researchers have developed a new implant that in the future could be used to deliver insulin to patients for up to a month, potentially enabling patients to control diabetes without injections, reports Tony Ho Tran for the Daily Beast. In the future, the researchers hope to “develop a device for humans that would be roughly the size of a stick of gum,” writes Tran. “The implant could also be used to deliver things like drugs or proteins to help treat other diseases in humans as well.”
Sean Hunt MS ’13 PhD ’16 co-founded Solugen, a startup working to develop industrial chemicals with environmentally friendly ingredients, reports David H. Freedman for Newsweek. “The company's goals over the next seven years are to reduce the carbon emissions released by industry into the environment by an amount equivalent to eliminating 2 million cars, and to make enough bioplastic to get rid of 5 billion non-degradable plastic bottles,” writes Freedman.
Researchers at MIT have developed a mobile vaccine printer capable of printing a vaccine onto a patch of microneedles that can be absorbed into the skin without injection, reports Sandra Tsing for NPR. “These printed vaccines could be used in areas that are unable to refrigerate traditional vaccines,” explains Tsing.
Institute Prof. Bob Langer speaks with Curiosity podcast hosts Immad Akhynd and Raj Suri about his work in the field of biotechnology, delving into how he has co-founded 40 companies. “I wanted to get out and do some good in the world,” says Langer. “That's where patents come in and that's where companies come in. And I think the challenge of the company is very different because you have what I call a platform technology.”